Immune checkpoint blockade (ICB) drugs targeting programmed cell death 1 (PD1), programmed cell death ligand 1 (PD‐L1), and cytotoxic T lymphocyte antigen 4 (CTLA4) are currently being tested for the treatment of recurrent/metastatic cervical cancers.[15, 16, 17] Unfortunately, the overall response rates to ICB therapy are low, varying from 4% to 26%.[15, 18, 19, 20] Clarifying the immune landscape of CSCC, especially the immunosuppression status in the tumor microenvironment (TME), may help us better address this phenomenon and adjust our treatment strategy for cervical cancers. This evidence concerns the gene CTLA4 and cervical cancer.